CytRx is a biopharmaceutical research and development company focusing on oncology. Co. focuses on the discovery, research and clinical development of anti-cancer drug candidates that utilize LADR (Linker Activated Drug Release) technology platform to develop the accumulation and release of cytotoxic anti-cancer agents at the tumor. Co. has worked to develop and focused on the research and clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of tumors. The CYTR stock yearly return is shown above.
The yearly return on the CYTR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYTR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|